Analyst: There’s a ‘mismatch’ between expectations and reality for Stryker’s Mako platform

stryker-mako-7x4A 51-physician Barclays survey of U.S. hip and knee surgeons today prompted analyst Matthew Taylor to question investors’ expectations for Stryker‘s (NYSE:SYK) Mako robot-assisted surgery platform.

Some 22% of the docs surveyed reported using the Mako system, most for partial knee replacement procedures, with 25.5% saying they would use it more in the future, Taylor wrote in a note to investors, “leading us to believe that MAKO uptake will be modest.”

“In our view, there is a mismatch between investor expectations for Mako (which are high) and the market reality (which is mixed). While our survey showed some signs of enthusiasm for robotics, doctors called this the most ‘over-hyped’ area,” he wrote.

And 47% of the surgeon respondents said they don’t believe Stryker’s Triathlon total knee offering for Mako will significantly increase Mako adoption, with 39% saying they believe it will.

By Brad Perriello | MassDevice

READ MORE

About Peter Coffaro 1104 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

1 Comment

  1. If doctors would have reported the adverse events that occurred during the early mako use it would not have been bought by Stryker. Maurice ferre hyped the product than left for another company.

Leave a Reply

Your email address will not be published.


*